Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | terminated | Phase 2 | 2 | University of PittsburghOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT01668173 | HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET | terminated | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| May 23, 2016 |
| clinicaltrials |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00510289 | Sorafenib in Myelodysplastic Syndrome | terminated | Phase 2 | 19 | Duke UniversityOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT00630994 | Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis | terminated | Phase 2 | 4 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT01880437 | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 3 | Dec 15, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | SpirogenINDUSTRY | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 6 | Mirati Therapeutics Inc.INDUSTRY | 3 | May 8, 2015 | clinicaltrials |
| NCT01488253 | Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants | terminated | Phase 2 | 3 | The Korean Society of Blood and Marrow TransplantationOTHER | 1 | Apr 3, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00114959 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | terminated | Phase 2 | 15 | ChemGenex PharmaceuticalsINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00509249 | Aflibercept in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00907582 | ASCT for Relapsed APL After Molecular Remission | terminated | Phase 2 | 5 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00593645 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00184054 | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia | terminated | Phase 2 | 11 | University of Southern CaliforniaOTHER | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT01193400 | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | terminated | Phase 2 | 75 | PETHEMA FoundationOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00949117 | Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer | terminated | Phase 2 | 9 | University of South FloridaOTHER | 0 | Apr 2, 2014 | clinicaltrials |
| NCT00818961 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 2 | 36 | Northside Hospital, Inc.OTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00720850 | Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)(LENAMAINT) | terminated | Phase 2 | 10 | Technische Universität DresdenOTHER | 1 | Sep 27, 2013 | clinicaltrials |
| NCT00066417 | Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia | terminated | Phase 2 | 51 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 1, 2013 | clinicaltrials |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | terminated | Phase 2 | 13 | The Emmes Company, LLCINDUSTRY | 1 | Apr 29, 2013 | clinicaltrials |
| NCT00006220 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | terminated | Phase 1 / Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Feb 6, 2013 | clinicaltrials |
| NCT00089388 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00023920 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005641 | Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2012 | clinicaltrials |
| NCT00005852 | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML(MPDMDSBMT) | terminated | Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00113321 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2012 | clinicaltrials |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 5 | Northside Hospital, Inc.OTHER | 1 | Mar 23, 2012 | clinicaltrials |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | terminated | Phase 2 | 39 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00245128 | Imatinib Mesylate in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin(FB-ATG) | terminated | Phase 2 | 20 | King's College Hospital NHS TrustOTHER | 1 | Aug 17, 2011 | clinicaltrials |
| NCT00381693 | Azacitidine in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 21, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2016source: clinicaltrials